Pharma BD Deal Intelligence

Pfizer Inc. / Wyeth

2009 · Acquisition/Merger · $68.0B · Complete

Announcement Sentiment

100

Strongly positive

Outcome Score

Worked — the deal delivered on its rationale.

Pfizer acquired Wyeth for approximately $68 billion in a cash-and-stock transaction, gaining a leading biologics portfolio including Prevnar and Enbrel, diversifying beyond small molecules into vaccines, biologics, and consumer health.

Did it work? Outcome assessment

Wyeth brought Prevnar, biologics platform, and $4B synergies but stock underperformed

Strategic verdict

Achieved Stated Rationale

Assessment window: 5yr post-close.

Key facts

Announced Jan 26, 2009
Closed Oct 15, 2009
Deal value $68.0B
Deal type Acquisition/Merger
Therapeutic area Cardiovascular, Immunology, Infectious Disease, Neurology, Oncology, Vaccines, Women's Health
Key assets Prevnar (pneumococcal vaccine), Enbrel (etanercept), Effexor (venlafaxine), Sutent (sunitinib), Geodon (ziprasidone), Zyvox (linezolid), bapineuzumab (Phase III), Grange Castle biologics manufacturing facility
Mechanism Pneumococcal conjugate vaccine, TNF inhibitor, SNRI antidepressant, Anti-amyloid beta monoclonal antibody

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals